GlaxoSmithKline Consumer Nigeria Plc, popularly known as GSK has changed its operational model with the selection of Fidson Healthcare Plc as local contract manufacturing partner. This follows the announcement made by GSK to all its stakeholders through the Nigerian Stock Exchange (NSE) last week.
“Following the earlier announcement on the restructuring of its supply chain operating model, GSK wishes to announce the selection of Fidson Healthcare as GSK’s preferred local contract manufacturing partner, as part of the changes in our consumer healthcare supply chain operating model. With this selection and subject to the meeting of appropriate regulatory requirement, GSK will be transitioning the manufacturing of its wellness and respiratory products in the first instance to Fidson from Q3 2021.
“Until then it would be business as usual at the Agbara factory as GSK continues to ensure supply continuity for all its locally manufactured brands. In choosing Fidson, GSK believes that the partnership would help build and sustain local expertise, technical knowledge and improve local production capacities”, the company said in a note to shareholders.
GSK announced further that all the changes communicated did not impact its broader commitments to global health in Nigeria as well as across Africa. An regardless of this announcement, GSK would continue to be a listed company on the NSE.
TELIAT SULE
